LH vs TEM
LH: Labcorp is a leading global life sciences company providing essential clinical diagnostic testing and drug development services to the healthcare industry. TEM: Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers.
Side-by-side fundamentals
| Metric | LH | TEM | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $313.96 | $46.70 | |
| Market cap as of 2026-08-06 | $25.7B | $8.4B | |
| P/E as of 2026-08-06 | 25.34 | n/a | |
| PEG as of 2026-08-06 | 3.11 | -1.51 | TEM lower |
| Net margin as of 2026-08-06 | +7.0% | -22.2% | LH higher |
| Gross margin as of 2026-08-06 | +28.9% | +63.4% | TEM higher |
| Operating margin as of 2026-08-06 | +10.4% | -20.6% | LH higher |
| ROE as of 2026-08-06 | +11.6% | -70.2% | LH higher |
| ROA as of 2026-08-06 | +5.4% | -14.6% | LH higher |
| Debt / equity as of 2026-08-06 | 0.69 | 2.96 | LH lower |
| Revenue growth (YoY) as of 2026-08-06 | +6.4% | +69.8% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | +58.3% | TEM higher |
| Dividend yield as of 2026-08-06 | +0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-08-06 | 0.86 | 2.84 | |
| 1-year return as of 2026-08-05 close | +19.2% | -19.1% | LH higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.